Integrase Defective Lentiviral Vectors for Antibody Delivery against Influenza

用于抗流感抗体递送的整合酶缺陷慢病毒载体

• 批准号: 9320742
• 负责人: MIRELLA SALVATORE
• 金额: $ 25.43万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-25 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9320742
• 关键词: Address; Antibodies; Antigens; Autoimmunity; Bioterrorism; Body Weight decreased; Cell Culture Techniques; Cells; Chronic Disease; Communicable Diseases; DNA; Data; Development; Disease Outbreaks; Dose; Drug resistance; Effectiveness; Emerging Communicable Diseases; Engineering; Epitopes; Future; Gene Delivery; Genes; Genetic; Genetic Transcription; Half-Life; Hemagglutinin; Immune response; Immunity; Immunization; Immunotherapy; In Vitro; Infection; Infectious Agent; Influenza; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A virus; Influenza prevention; Injection of therapeutic agent; Integrase; Interphase Cell; Intramuscular; Lentivirus Vector; Lung; Malignant Neoplasms; Measures; Mediating; Medical; Methods; Modeling; Monoclonal Antibodies; Morbidity - disease rate; Mus; Nucleoproteins; Passive Immunization; Passive Immunotherapy; Pathogenicity; Patients; Population; Proteins; Public Health; Publishing; Resistance; Route; Safety; Serum; Surface; System; Testing; Therapeutic; Therapeutic antibodies; Time; Vaccination; Variant; Viral; Viral Vector; Virus; Virus Diseases; base; cancer immunotherapy; cellular transduction; disorder prevention; experimental study; genetic immunization strategies; in vivo; influenza A virus nucleoprotein; interest; monoclonal antibody production; mortality; neutralizing monoclonal antibodies; novel; pandemic influenza; pathogen; prevent; prophylactic; public health relevance; response; tool; transgene expression; vaccine development; vector

 DESCRIPTION (provided by applicant): Globalization, drug resistance, and bioterrorism all contribute to the growing threat from infectious diseases, but despite medical advances, we are often still unable to rapidly protect non-immune populations. Passive immunotherapy is a fast and successful method of protection, but monoclonal antibodies (mAbs) are expensive and require high, repeated doses to be effective. Therefore, this approach is not suitable for large-scale use. The delivery of mAbs using a viral vector has been recently proposed as an attractive alternative to the direct injection of mAbs. To this end, a variety of viral vectors have been used to express mAbs; however, vector immunity and safety issues have hampered the development of this strategy. The main of objective of this proposal is to address the feasibility of using integrase-defective lentiviral vectors (IDLV) to deliver mAbs. IDLV have several advantages over other viral vectors, including the absence of pre-existing anti-vector immunity and the safety features of non-integration and non-replication. IDLV are also maintained in non-dividing cells, and can express steady levels of functional proteins in vivo for months. As proof of the feasibility of using IDLV to express mAbs that protect against infectious disease, we will engineer IDLV to express mAbs against the influenza A virus (IAV) hemagglutinin (HA), and will test their ability to protect against IAV infection. An advantage of using IAV as a model is that HA-specific antibody- mediated mechanisms of protection are well-defined. Furthermore, both passive immunization and hyperimmune sera have been successfully used to prevent and treat IAV. In our preliminary data, we show that IDLV can express anti-HA mAbs in vitro in transduced cells, and we quantify the levels. Based on an estimate of the amount of mAbs needed for protection, we hypothesize that IDLV will produce an adequate level of mAbs to protect against IAV challenge in mice. In addition, since we showed that IDLV expressing influenza NP could elicit protective immunity against IAV, we will test the effectiveness of combining the genetic delivery of a mAb and a conserved influenza antigen to protect against IAV. We will test our hypothesis through the following aims: 1. measure the levels and persistence of mAbs produced from IDLV in the serum or lungs of mice and determine the optimal dose for use in challenge experiments, 2. assess the ability of IDLV expressing anti-HA mAbs to protect against lethal IAV challenge, and 3. evaluate the ability of co-administration of IDLV expressing anti-HA mAbs and IDLV expressing NP to protect from IAV at different times after administration. If successful, our study would be the first to show the effectiveness of IDL as a tool for genetic delivery of mAbs that protect against infectious agents. Additionally, expression of mAbs along with a protective antigen is a novel application in disease prevention that could have a broad impact on the prevention of IAV and other infectious diseases. Given the safety feature of non-integration, the successful development of this vector would represent a significant step in gene delivery and vaccine development.

 描述(申请人提供)：全球化、抗药性和生物恐怖主义都加剧了传染病的日益增长的威胁，但尽管医学取得了进步，我们往往仍然无法迅速保护非免疫人群。被动免疫疗法是一种快速而成功的保护方法，但单抗(MAbs)价格昂贵，需要高剂量、重复剂量才能有效。因此，这种方法不适合大规模使用。利用病毒载体传递单抗是最近提出的一种有吸引力的替代直接注射单抗的方法。为此，已经使用了各种病毒载体 表达单抗；然而，媒介免疫和安全性问题阻碍了这一策略的发展。本方案的主要目的是探讨利用整合酶缺陷型慢病毒载体(IDLV)传递单抗的可行性。与其他病毒载体相比，IDLV具有几个优点，包括不存在预先存在的抗媒介免疫以及非整合和非复制的安全特征。IDLV也维持在未分裂的细胞中，并能在体内表达稳定水平的功能蛋白数月。为了证明用IDLV表达抗传染性疾病的单抗的可行性，我们将改造IDLV表达抗甲型流感病毒(IAV)血凝素(HA)的单抗，并测试其对IAV感染的保护能力。使用IAV作为模型的一个优点是，HA特异性抗体介导的保护机制是明确的。此外，被动免疫和高免血清都被成功地用于预防和治疗IAV。在我们的初步数据中，我们发现IDLV在体外可以在转导细胞中表达抗HA单抗，并对其水平进行了定量。根据对保护所需单抗数量的估计，我们假设IDLV将产生足够水平的单抗来保护小鼠免受IAV的攻击。此外，由于我们发现表达流感病毒NP的IDLV可以诱导对IAV的保护性免疫，所以我们将测试mAb和保守的流感抗原相结合的预防IAV的有效性。我们将通过以下目的来验证我们的假设：1.测量IDLV产生的单抗在小鼠血清或肺中的水平和持久性，并确定用于攻击实验的最佳剂量；2.评估表达抗HA单抗的IDLV对致死性IAV攻击的保护能力；3.评估表达抗HA单抗的IDLV和表达NP的IDLV在给药后不同时间联合接种对IAV的保护能力。如果成功，我们的研究将是第一个显示IDL作为一种遗传工具传递单抗的有效性，以防止感染性病原体。此外，单抗的表达与保护性抗原一起在疾病预防中是一种新的应用，可能会对预防IAV和其他传染病产生广泛的影响。鉴于非整合的安全特性，该载体的成功开发将代表着基因传递和疫苗开发的重要一步。